Detect
Detect is a women's health diagnostics company developing a point-of-care CRISPR-based molecular multiplex platform, starting with a vaginitis test sold to OB/GYN offices, healthcare institutions, and consumers via telemedicine prescription.
- Company typePrivate
- Founded2020
- HeadquartersGuilford, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Detect does
Detect Inc. is a privately held women's health molecular diagnostics company founded in 2020 and headquartered in Guilford, Connecticut. It develops the Detect Hub, a compact point-of-care device built on a CRISPR-based molecular multiplex platform capable of detecting multiple pathogens simultaneously and returning results within minutes during a patient visit. The workflow is designed for clinician use with no sample preparation, no liquid handling, and less than one minute of hands-on time, supported by Detect-made custom reagents designed via AI-enabled primer design.
The company's first commercial product is a vaginitis diagnostic test, targeting the leading cause of OB/GYN office visits, with a stated roadmap to extend the platform into sexual health and hormonal health conditions. Its customer base is hybrid: OB/GYN offices and healthcare institutions purchase devices and consumables through direct sales and institutional accounts on detect.com, while individual consumers access the same products via the website paired with telemedicine prescription authorization through PWN Health.
Detect monetizes through hardware sales (Detect Hub devices) and recurring consumables (custom reagents and test kits), with US-only distribution. The company is venture-backed, having closed a Series B in November 2022 led by Eldridge Industries and Human Capital with participation from Expa, Flu Lab, Foresite Capital, Glenview Capital, Goat Capital, and Horizons Ventures, and is led by CEO Michelle Garsha with founder/chairman Jonathan Rothberg.
Detect firmographics
Firmographics- Name
- Detect
- Legal name
- Detect Inc.
- Website
- https://detect.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Detect is a women's health diagnostics company developing a point-of-care CRISPR-based molecular multiplex platform, starting with a vaginitis test sold to OB/GYN offices, healthcare institutions, and consumers via telemedicine prescription.
- Ownership category
- akta.pro rank
Detect industry classification
Industry- Product category
- Women's Health Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
- akta.pro secondary industries
- Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection) (HLAHAOAF), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)
Keywords
Where Detect is headquartered
LocationHeadquarters
- HQ city
- Guilford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Detect business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Diagnostic Testing Products: Sale of molecular diagnostic testing kits and platforms to healthcare providers (OB/GYN offices, institutions) and consumers with prescription. Products include testing devices and associated reagents for women's health conditions.
- Telehealth Consultation Services: The website facilitates telemedicine consultation services through healthcare provider partners, enabling prescription authorization for prescription-only tests. Revenue may be generated through service fees or partnership arrangements.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels3 records
Detect product offering
Product offeringCore offering
Detect has developed a consumer-grade molecular diagnostics platform centered on a compact point-of-care device (Detect Hub) that uses CRISPR-based detection and AI-designed reagents to deliver multiplex test results within minutes, without sample preparation or liquid handling. The company's current focus is women's health diagnostics, starting with vaginitis testing, with a roadmap extending into sexual and hormonal health conditions.
Product overview
Detect offers a molecular multiplex diagnostic platform centered on the Detect Hub device, which delivers rapid, point-of-care molecular testing results. The platform currently focuses on women's health diagnostics, starting with vaginitis testing as the primary product, with plans to expand into sexual and hormonal health conditions. The system provides molecular-level accuracy with a workflow that requires no sample preparation or liquid handling, delivering results within minutes at the point of need. The Detect Hub serves as the core hardware platform, supported by Detect-made custom reagents and AI-enabled primer design technology.
Differentiator
Problem solved
Functional benefit
Products and services
- Detect Hub
Quantifiable outcome
- Less than 1 minute hands-on time for testing
- +2 more outcomes
Companies that use Detect
Customer profileSegments3 records
Ideal customer profiles3 records
Detect technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Detect partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- PWN HealthcoreHealthcare provider partner facilitating telemedicine consultation services and prescription authorization for prescription-only diagnostic tests. PWN Health and other healthcare providers enable Detect to offer prescription-based products to individual patients through their platform.
- StripeminorPayment processing vendor handling credit card, debit card, and monetary transactions through the Detect website. Stripe processes payments for product purchases and services on the platform.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Detect competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Detect social profiles
Digital presenceDetect financial estimates
Financial estimateRevenue estimate
Valuation estimate
Detect leadership team
Management profileNumber of profiles
Profiles9 records
Detect funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Detect M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Detect
What does Detect do?
Detect has developed a consumer-grade molecular diagnostics platform centered on a compact point-of-care device (Detect Hub) that uses CRISPR-based detection and AI-designed reagents to deliver multiplex test results within minutes, without sample preparation or liquid handling. The company's current focus is women's health diagnostics, starting with vaginitis testing, with a roadmap extending into sexual and hormonal health conditions.
Is Detect a public or private company?
Detect is a private company. It is classified as venture growth investor backed and is currently operating.
When was Detect founded?
Detect was founded in 2020. It employs 11 to 50 people.
Where is Detect based?
Detect is headquartered in Guilford, United States, in the North America region.
How does Detect make money?
Two revenue lines are on record. Diagnostic Testing Products are the primary driver. The others are telehealth Consultation Services.
Does Detect have an API?
No public API is recorded for Detect.
What industry is Detect in?
Detect's product category is Women's Health Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAI, Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges), with a secondary code of HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection). Its NAICS code is 325413 and its SIC code is 2835.